Bio-Path Holdings Expands Reach of Non-Toxic Cancer Treatment
Bio-Path Holdings Inc., (OTCQX: BPTH) (“Bio-Path”), recently announced development of its lead cancer drug, BP-100-1.01 (Liposomal Grb-2), for the treatment of triple negative and inflammatory breast cancer, both of which currently have no treatment and high mortality rates. The drug is currently being tested in clinical trials on blood cancers, and many late stage cancer patients in the trial have stabilized their disease.
View full press release